Genome-wide association study identifies novel pharmacogenomic loci for therapeutic response to montelukast in Asthma

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Dahlin, Amber ^a   Litonjua, Augusto ^a   Lima, John J ^b   Tamari, Mayumi ^c   Kubo, Michiaki ^c   Irvin, Charles G ^d   Peters, Stephen P ^e   Tantisira, Kelan G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NEMOURS CHILDREN S CLINIC   (United States)

^c RIKEN Center for Integrative Medical Sciences   (Japan)

^d UNIVERSITY OF VERMONT   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; ACETIC ACID DERIVATIVE; QUINOLINE DERIVATIVE;

ADULT; ARTICLE; ASTHMA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; GENE LOCUS; GENETIC ASSOCIATION; HEREDITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; DRUG EFFECTS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; LUNG; PATHOPHYSIOLOGY; PHARMACOGENETICS; TREATMENT OUTCOME;

ACETATES; ADULT; ASTHMA; FEMALE; GENETIC LOCI; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LUNG; MALE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINOLINES; TREATMENT OUTCOME;

EID: 84939239612     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129385     Document Type: Article

References (41)

1. Peters SP, Anthonisen N, Castro M, Holbrook JT, Irvin CG, Smith LJ, et al. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med. 2007; 356(20):2027-39. PMID: 17507702.
2. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6- To 14-year-old children: A randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA. 1998; 279(15):1181-6. PMID: 9555757.
3. Drazen J. Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Am J Respir Crit Care Med. 1998; 157(6 Pt 2):S233-7; discussion S47-8. PMID: 9647605.
4. Nelson H, Kemp J, Berger W, Corren J, Casale T, Dube L, et al. Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: A 3-month randomized controlled study. Ann Allergy Asthma Immunol. 2007; 99(2):178-84. PMID: 17718106.
5. Israel E, Cohn J, Dubé L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA. 1996; 275 (12):931-6. PMID: 8598621.
6. Salmon JA, Higgs GA. Prostaglandins and leukotrienes as inflammatory mediators. Br Med Bull. 1987; 43(2):285-96. PMID: 2825898.
7. Hammarström S. Biosynthesis and metabolism of leukotrienes. Monogr Allergy. 1983; 18:265-71. PMID: 6316129.
8. Hammarström S. Leukotrienes. Annu Rev Biochem. 1983; 52:355-77. PMID: 6311078.
9. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull. 2000; 56(4):1054-70. PMID: 11359637.
10. Lima JJ. Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. Mol Diagn Ther. 2007; 11(2):97-104. PMID: 17397245.
11. Drazen JM, Yandava CN, Dubé L, Szczerback N, Hippensteel R, Pillari A, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999; 22(2):168-70. PMID: 10369259.
12. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002; 109(3):410- 8. PMID: 11897984.
13. Klotsman M, York TP, Pillai SG, Vargas-Irwin C, Sharma SS, van den Oord EJ, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics. 2007; 17(3):189-96. PMID: 17460547.
14. Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006; 173(4):379- 85. PMID: 16293801.
15. Tantisira KG, Lima J, Sylvia J, Klanderman B, Weiss ST. 5-lipoxygenase pharmacogenetics in asthma: Overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics. 2009; 19(3):244-7. doi:10.1097/FPC.0b013e328326e0b1 PMID: 19214143.
16. Lima JJ, Blake KV, Tantisira KG, Weiss ST. Pharmacogenetics of asthma. Curr Opin Pulm Med. 2009; 15(1):57-62. doi:10.1097/MCP.0b013e32831da8be PMID: 19077707.
17. Tantisira KG, Lake S, Silverman ES, Palmer LJ, Lazarus R, Silverman EK, et al. Corticosteroid Pharmacogenetics: Association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004; 13(13):1353-9. PMID: 15128701.
18. Mougey EB, Chen C, Tantisira KG, Blake KV, Peters SP, Wise RA, et al. Pharmacogenetics of asthma controller treatment. Pharmacogenomics J. 2013; 13(3):242-50. doi:10.1038/tpj.2012.5 PMID: 22370858.
19. Duroudier NP, Tulah AS, Sayers I. Leukotriene pathway genetics and pharmacogenetics in allergy. Allergy. 2009; 64(6):823-39. doi:10.1111/j.1398-9995.2009.02015.x PMID: 19416143.
20. Holloway JW, Barton SJ, Holgate ST, Rose-Zerilli MJ, Sayers I. The role of LTA4H and ALOX5AP polymorphism in asthma and allergy susceptibility. Allergy. 2008; 63(8):1046-53. doi:10.1111/j.1398-9995.2008.01667.x PMID: 18547289.
21. Tcheurekdjian H, Via M, De Giacomo A, Corvol H, Eng C, Thyne S, et al. ALOX5AP and LTA4H polymorphisms modify augmentation of bronchodilator responsiveness by leukotriene modifiers in Latinos. J Allergy Clin Immunol. 2010; 126(4):853-8. doi:10.1016/j.jaci.2010.06.048 PMID: 20810156.
22. Via M, De Giacomo A, Corvol H, Eng C, Seibold MA, Gillett C, et al. The role of LTA4H and ALOX5AP genes in the risk for asthma in Latinos. Clin Exp Allergy. 2010; 40(4):582-9. doi:10.1111/j.1365-2222.2009.03438.x PMID: 20067482.
23. Kang MJ, Kwon JW, Kim BJ, Yu J, Choi WA, Shin YJ, et al. Polymorphisms of the PTGDR and LTC4S influence responsiveness to leukotriene receptor antagonists in Korean children with asthma. J Hum Genet. 2011; 56(4):284-9. doi:10.1038/jhg.2011.3 PMID: 21307858.
24. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption ofmontelukast is transporter mediated: A common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009; 19(2):129-38. doi:10.1097/FPC.0b013e32831bd98c PMID: 19151602.
25. Palikhe NS, Kim JH, Park HS. Update on recent advances in the management of aspirin exacerbated respiratory disease. Yonsei Med J. 2009; 50(6):744-50. doi:10.3349/ymj.2009.50.6.744 PMID: 20046412.
26. Shrestha Palikhe N, Kim SH, Jin HJ, Hwang EK, Nam YH, Park HS. Genetic mechanisms in aspirinexacerbated respiratory disease. J Allergy (Cairo). 2012; 2012:794890. doi:10.1155/2012/794890PMID: 21837245.
27. Kim SH, Park HS. Genetic markers for differentiating aspirin-hypersensitivity. Yonsei Med J. 2006; 47 (1):15-21. PMID: 16502481.
28. Kang MJ, Lee SY, Kim HB, Yu J, Kim BJ, Choi WA, et al. Association of IL-13 polymorphisms with leukotriene receptor antagonist drug responsiveness in Korean children with exercise-induced bronchoconstriction. Pharmacogenet Genomics. 2008; 18(7):551-8. doi:10.1097/FPC.0b013e3282fe94c5PMID: 18551035.
29. Centers ALAACR. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med. 2007; 175(3):235-42. PMID: 16998094.
30. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005; 115(2):233-42. PMID: 15696076.
31. Sorkness CA, Lemanske RF, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial. J Allergy Clin Immunol. 2007; 119(1):64-72. PMID: 17140647.
32. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: A tool set for wholegenome association and population-based linkage analyses. Am J Hum Genet. 2007; 81(3):559-75. PMID: 17701901.
33. Park HW, Dahlin A, Tse S, Duan QL, Schuemann B, Martinez FD, et al. Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. J Allergy Clin Immunol. 2014.
34. Tantisira KG, Damask A, Szefler SJ, Schuemann B, Markezich A, Su J, et al. Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus. American journal of respiratory and critical care medicine. 2012; 185(12):1286-91. doi:10.1164/rccm.201111-2061OC PMID: 22538805.
35. Liptak T. On the combination of independent tests. Magyar Tud Akad Mat Kutato Int Kozl. 1958; 3:171-97.
36. Pina C, May G, Soneji S, Hong D, Enver T. MLLT3 regulates early human erythroid and megakaryocytic cell fate. Cell Stem Cell. 2008; 2(3):264-73. doi:10.1016/j.stem.2008.01.013 PMID: 18371451.
37. Sheppard KA, Greenberg SM, Funk CD, Romano M, Serhan CN. Lipoxin generation by human megakaryocyte- induced 12-lipoxygenase. Biochim Biophys Acta. 1992; 1133(2):223-34. PMID: 1310055.
38. Dupuis F, Desplat V, Praloran V, Denizot Y. Effects of lipidic mediators on the growth of human myeloid and erythroid marrow progenitors. J Lipid Mediat Cell Signal. 1997; 16(3):117-25. PMID: 9246601.
39. Moritani C, Ishioka S, Haruta Y, Kambe M, Yamakido M. Activation of platelets in bronchial asthma. Chest. 1998; 113(2):452-8. PMID: 9498966.
40. Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL, et al. SCAN: SNP and copy number annotation. Bioinformatics. 2010; 26(2):259-62. doi:10.1093/bioinformatics/btp644 PMID: 19933162.
41. Hildebrand JD, Soriano P. Shroom, a PDZ domain-containing actin-binding protein, is required for neural tube morphogenesis in mice. Cell. 1999; 99(5):485-97. PMID: 10589677.